<?xml version="1.0" encoding="utf-8"?>
<Label drug="Vasotec" setid="39631f1f-5d19-43c1-b504-bf56d991ed97">
<Text><Section name="Boxed Warning section" id="34066-1">
WARNING: FETAL TOXICITY 

 See full prescribing information for complete boxed warning. 

 • When pregnancy is detected, discontinue VASOTEC as soon as possible. 

 • Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. See 
 WARNINGS: Fetal Toxicity</Section>
<Section name="CONTRAINDICATIONS SECTION" id="34070-3">
CONTRAINDICATIONS 

 VASOTEC is contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous treatment with an angiotensin converting enzyme inhibitor and in patients with hereditary or idiopathic angioedema. 
 Do not coadminister aliskiren with VASOTEC in patients with diabetes (see 
 PRECAUTIONS, Drug Interactions 
 ). 
 VASOTEC is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer VASOTEC within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor (see 
 WARNINGS 
 ).</Section>
<Section name="WARNINGS SECTION" id="34071-1">
WARNINGS 

 Anaphylactoid and Possibly Related Reactions 

 Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of eicosanoids and polypeptides, including endogenous bradykinin, patients receiving ACE inhibitors (including VASOTEC) may be subject to a variety of adverse reactions, some of them serious. 

 Head and Neck Angioedema 

 Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has been reported in patients treated with angiotensin converting enzyme inhibitors, including VASOTEC. This may occur at any time during treatment. In such cases VASOTEC should be promptly discontinued and appropriate therapy and monitoring should be provided until complete and sustained resolution of signs and symptoms has occurred. In instances where swelling has been confined to the face and lips the condition has generally resolved without treatment, although antihistamines have been useful in relieving symptoms. Angioedema associated with laryngeal edema may be fatal. Where there is involvement of the tongue, glottis or larynx, likely to cause airway obstruction, appropriate therapy, e.g., subcutaneous epinephrine solution 1:1000 (0.3 mL to 0.5 mL) and/or measures necessary to ensure a patent airway, should be promptly provided (see 
 ADVERSE REACTIONS 
 ). 
 Patients receiving coadministration of ACE inhibitor and mTOR (mammalian target of rapamycin) inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy or a neprilysin inhibitor may be at increased risk for angioedema (see 
 PRECAUTIONS 
 ). 

 Intestinal Angioedema: 
 Intestinal angioedema has been reported in patients treated with ACE inhibitors. These patients presented with abdominal pain (with or without nausea or vomiting); in some cases there was no prior history of facial angioedema and C-1 esterase levels were normal. The angioedema was diagnosed by procedures including abdominal CT scan or ultrasound, or at surgery, and symptoms resolved after stopping the ACE inhibitor. Intestinal angioedema should be included in the differential diagnosis of patients on ACE inhibitors presenting with abdominal pain. 
 Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk of angioedema while receiving an ACE inhibitor (see also 
 INDICATIONS AND USAGE 
 and 
 CONTRAINDICATIONS 
 ). 

 Anaphylactoid Reactions During Desensitization 

 Two patients undergoing desensitizing treatment with hymenoptera venom while receiving ACE inhibitors sustained life-threatening anaphylactoid reactions. In the same patients, these reactions were avoided when ACE inhibitors were temporarily withheld, but they reappeared upon inadvertent rechallenge. 

 Anaphylactoid Reactions During Membrane Exposure 

 Anaphylactoid reactions have been reported in patients dialyzed with high-flux membranes and treated concomitantly with an ACE inhibitor. Anaphylactoid reactions have also been reported in patients undergoing low-density lipoprotein apheresis with dextran sulfate absorption. 

 Hypotension 

 Excessive hypotension is rare in uncomplicated hypertensive patients treated with VASOTEC alone. Patients with heart failure given VASOTEC commonly have some reduction in blood pressure, especially with the first dose, but discontinuation of therapy for continuing symptomatic hypotension usually is not necessary when dosing instructions are followed; caution should be observed when initiating therapy (see 
 DOSAGE AND ADMINISTRATION 
 ). Patients at risk for excessive hypotension, sometimes associated with oliguria and/or progressive azotemia, and rarely with acute renal failure and/or death, include those with the following conditions or characteristics: heart failure, hyponatremia, high-dose diuretic therapy, recent intensive diuresis or increase in diuretic dose, renal dialysis, or severe volume and/or salt depletion of any etiology. It may be advisable to eliminate the diuretic (except in patients with heart failure), reduce the diuretic dose or increase salt intake cautiously before initiating therapy with VASOTEC in patients at risk for excessive hypotension who are able to tolerate such adjustments (see 
 PRECAUTIONS, Drug Interactions 
 and 
 ADVERSE REACTIONS 
 ). In patients at risk for excessive hypotension, therapy should be started under very close medical supervision and such patients should be followed closely for the first two weeks of treatment and whenever the dose of enalapril and/or diuretic is increased. Similar considerations may apply to patients with ischemic heart or cerebrovascular disease, in whom an excessive fall in blood pressure could result in a myocardial infarction or cerebrovascular accident. 
 If excessive hypotension occurs, the patient should be placed in the supine position and, if necessary, receive an intravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further doses of VASOTEC, which usually can be given without difficulty once the blood pressure has stabilized. If symptomatic hypotension develops, a dose reduction or discontinuation of VASOTEC or concomitant diuretic may be necessary. 

 Neutropenia/Agranulocytosis 

 Another angiotensin converting enzyme inhibitor, captopril, has been shown to cause agranulocytosis and bone marrow depression, rarely in uncomplicated patients but more frequently in patients with renal impairment, especially if they also have a collagen vascular disease. Available data from clinical trials of enalapril are insufficient to show that enalapril does not cause agranulocytosis at similar rates. Marketing experience has revealed cases of neutropenia or agranulocytosis in which a causal relationship to enalapril cannot be excluded. Periodic monitoring of white blood cell counts in patients with collagen vascular disease and renal disease should be considered. 

 Hepatic Failure 

 Rarely, ACE inhibitors have been associated with a syndrome that starts with cholestatic jaundice and progresses to fulminant hepatic necrosis, and (sometimes) death. The mechanism of this syndrome is not understood. Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up. 

 Fetal Toxicity 

 Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue VASOTEC as soon as possible. These adverse outcomes are usually associated with use of these drugs in the second and third trimester of pregnancy. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. Appropriate management of maternal hypertension during pregnancy is important to optimize outcomes for both mother and fetus. 
 In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. Perform serial ultrasound examinations to assess the intra-amniotic environment. If oligohydramnios is observed, discontinue VASOTEC, unless it is considered lifesaving for the mother. Fetal testing may be appropriate, based on the week of pregnancy. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury. Closely observe infants with histories of in utero exposure to VASOTEC for hypotension, oliguria, and hyperkalemia (see 

 PRECAUTIONS, Pediatric Use 
 ). 
 No teratogenic effects of enalapril were seen in studies of pregnant rats and rabbits. On a body surface area basis, the doses used were 57 times and 12 times, respectively, the maximum recommended human daily dose (MRHDD).</Section>
<Section name="PRECAUTIONS SECTION" id="42232-9">
PRECAUTIONS 

 General 

 Aortic Stenosis/Hypertrophic Cardiomyopathy: 

 As with all vasodilators, enalapril should be given with caution to patients with obstruction in the outflow tract of the left ventricle. 

 Impaired Renal Function: 

 As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. In patients with severe heart failure whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with angiotensin converting enzyme inhibitors, including VASOTEC, may be associated with oliguria and/or progressive azotemia and rarely with acute renal failure and/or death (see 
 PRECAUTIONS, Drug Interactions 
 ). 
 In clinical studies in hypertensive patients with unilateral or bilateral renal artery stenosis, increases in blood urea nitrogen and serum creatinine were observed in 20 percent of patients. These increases were almost always reversible upon discontinuation of enalapril and/or diuretic therapy. In such patients renal function should be monitored during the first few weeks of therapy. 
 Some patients with hypertension or heart failure with no apparent pre-existing renal vascular disease have developed increases in blood urea and serum creatinine, usually minor and transient, especially when VASOTEC has been given concomitantly with a diuretic. This is more likely to occur in patients with pre-existing renal impairment. Dosage reduction and/or discontinuation of the diuretic and/or VASOTEC may be required. 

 Evaluation of patients with hypertension or heart failure should always include assessment of renal function (see 
 DOSAGE AND ADMINISTRATION 
 ). 

 Hyperkalemia: 

 Elevated serum potassium (greater than 5.7 mEq/L) was observed in approximately one percent of hypertensive patients in clinical trials. In most cases these were isolated values which resolved despite continued therapy. Hyperkalemia was a cause of discontinuation of therapy in 0.28 percent of hypertensive patients. In clinical trials in heart failure, hyperkalemia was observed in 3.8 percent of patients but was not a cause for discontinuation. 
 Risk factors for the development of hyperkalemia include renal insufficiency, diabetes mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes, which should be used cautiously, if at all, with VASOTEC (see 
 Drug Interactions 
 ). 

 Cough: 

 Presumably due to the inhibition of the degradation of endogenous bradykinin, persistent nonproductive cough has been reported with all ACE inhibitors, always resolving after discontinuation of therapy. ACE inhibitor-induced cough should be considered in the differential diagnosis of cough. 

 Surgery/Anesthesia: 

 In patients undergoing major surgery or during anesthesia with agents that produce hypotension, enalapril may block angiotensin II formation secondary to compensatory renin release. If hypotension occurs and is considered to be due to this mechanism, it can be corrected by volume expansion. 

 Information for Patients 

 Angioedema: 

 Angioedema, including laryngeal edema, may occur at any time during treatment with angiotensin converting enzyme inhibitors, including enalapril. Patients should be so advised and told to report immediately any signs or symptoms suggesting angioedema (swelling of face, extremities, eyes, lips, tongue, difficulty in swallowing or breathing) and to take no more drug until they have consulted with the prescribing physician. 

 Hypotension: 

 Patients should be cautioned to report lightheadedness, especially during the first few days of therapy. If actual syncope occurs, the patients should be told to discontinue the drug until they have consulted with the prescribing physician. All patients should be cautioned that excessive perspiration and dehydration may lead to an excessive fall in blood pressure because of reduction in fluid volume. Other causes of volume depletion such as vomiting or diarrhea may also lead to a fall in blood pressure; patients should be advised to consult with the physician. 

 Hyperkalemia: 

 Patients should be told not to use salt substitutes containing potassium without consulting their physician. 

 Neutropenia: 

 Patients should be told to report promptly any indication of infection (e.g., sore throat, fever) which may be a sign of neutropenia. 

 Pregnancy: 

 Female patients of childbearing age should be told about the consequences of exposure to VASOTEC during pregnancy. Discuss treatment options with women planning to become pregnant. Patients should be asked to report pregnancies to their physicians as soon as possible. 
 NOTE: As with many other drugs, certain advice to patients being treated with enalapril is warranted. This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects. 

 Drug Interactions 

 Neprilysin Inhibitors: 

 Patients taking concomitant neprilysin inhibitors may be at increased risk for angioedema. (see 
 WARNINGS 
 ) 

 Dual Blockade of the Renin-Angiotensin System (RAS) 

 Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Most patients receiving the combination of two RAS inhibitors do not obtain any additional benefit compared to monotherapy. In general, avoid combined use of RAS inhibitors. Closely monitor blood pressure, renal function, and electrolytes in patients on VASOTEC and other agents that affect the RAS. 
 Do not coadminister aliskiren with VASOTEC in patients with diabetes. Avoid use of aliskiren with VASOTEC in patients with renal impairment (GFR &lt;60 mL/min). 

 Hypotension — Patients on Diuretic Therapy: 
 Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril. The possibility of hypotensive effects with enalapril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril. If it is necessary to continue the diuretic, provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour (see 
 WARNINGS 
 and 
 DOSAGE AND ADMINISTRATION 
 ). 

 Agents Causing Renin Release: 
 The antihypertensive effect of VASOTEC is augmented by antihypertensive agents that cause renin release (e.g., diuretics). 

 Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors): 

 In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including enalapril, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving enalapril and NSAID therapy. 
 In a clinical pharmacology study, indomethacin or sulindac was administered to hypertensive patients receiving VASOTEC. In this study there was no evidence of a blunting of the antihypertensive action of VASOTEC. However, reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors. 

 Other Cardiovascular Agents: 
 VASOTEC has been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions. 

 Agents Increasing Serum Potassium: 
 VASOTEC attenuates potassium loss caused by thiazide-type diuretics. Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. Therefore, if concomitant use of these agents is indicated because of demonstrated hypokalemia, they should be used with caution and with frequent monitoring of serum potassium. Potassium-sparing agents should generally not be used in patients with heart failure receiving VASOTEC. 

 Lithium: 
 Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors. A few cases of lithium toxicity have been reported in patients receiving concomitant VASOTEC and lithium and were reversible upon discontinuation of both drugs. It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium. 

 Gold: 
 Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including VASOTEC. 

 mTOR (mammalian target of rapamycin) inhibitors: 

 Patients receiving coadministration of ACE inhibitor and mTOR inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema (see 
 WARNINGS 
 ). 

 Carcinogenesis, Mutagenesis, Impairment of Fertility 

 There was no evidence of a tumorigenic effect when enalapril was administered for 106 weeks to male and female rats at doses up to 90 mg/kg/day or for 94 weeks to male and female mice at doses up to 90 and 180 mg/kg/day, respectively. These doses are 26 times (in rats and female mice) and 13 times (in male mice) the maximum recommended human daily dose (MRHDD) when compared on a body surface area basis. 
 Neither enalapril maleate nor the active diacid was mutagenic in the Ames microbial mutagen test with or without metabolic activation. Enalapril was also negative in the following genotoxicity studies: rec-assay, reverse mutation assay with E. coli , sister chromatid exchange with cultured mammalian cells, and the micronucleus test with mice, as well as in an in vivo cytogenic study using mouse bone marrow. 
 There were no adverse effects on reproductive performance of male and female rats treated with up to 90 mg/kg/day of enalapril (26 times the MRHDD when compared on a body surface area basis). 

 Pregnancy 

 Nursing Mothers 
 Enalapril and enalaprilat have been detected in human breast milk. Because of the potential for serious adverse reactions in nursing infants from enalapril, a decision should be made whether to discontinue nursing or to discontinue VASOTEC, taking into account the importance of the drug to the mother. 

 Pediatric Use 

 Neonates with a history of in utero exposure to VASOTEC: 

 If oliguria or hypotension occurs, direct attention toward support of blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing hypotension and/or substituting for disordered renal function. Enalapril, which crosses the placenta, has been removed from neonatal circulation by peritoneal dialysis with some clinical benefit, and theoretically may be removed by exchange transfusion, although there is no experience with the latter procedure. 
 Antihypertensive effects of VASOTEC have been established in hypertensive pediatric patients age 1 month to 16 years. Use of VASOTEC in these age groups is supported by evidence from adequate and well-controlled studies of VASOTEC in pediatric and adult patients as well as by published literature in pediatric patients (see 
 CLINICAL PHARMACOLOGY, Clinical Pharmacology in Pediatric Patients 
 and 
 DOSAGE AND ADMINISTRATION 
 ). 
 VASOTEC is not recommended in neonates and in pediatric patients with glomerular filtration rate &lt;30 mL/min/1.73 m 2 , as no data are available.</Section>
<Section name="DOSAGE &amp; ADMINISTRATION SECTION" id="34068-7">
DOSAGE AND ADMINISTRATION 

 Hypertension 

 In patients who are currently being treated with a diuretic, symptomatic hypotension occasionally may occur following the initial dose of VASOTEC. The diuretic should, if possible, be discontinued for two to three days before beginning therapy with VASOTEC to reduce the likelihood of hypotension (see 
 WARNINGS 
 ). If the patient's blood pressure is not controlled with VASOTEC alone, diuretic therapy may be resumed. 
 If the diuretic cannot be discontinued an initial dose of 2.5 mg should be used under medical supervision for at least two hours and until blood pressure has stabilized for at least an additional hour (see 
 WARNINGS 
 and 
 PRECAUTIONS, Drug Interactions 
 ). 
 The recommended initial dose in patients not on diuretics is 5 mg once a day. Dosage should be adjusted according to blood pressure response. The usual dosage range is 10 to 40 mg per day administered in a single dose or two divided doses. In some patients treated once daily, the antihypertensive effect may diminish toward the end of the dosing interval. In such patients, an increase in dosage or twice daily administration should be considered. If blood pressure is not controlled with VASOTEC alone, a diuretic may be added. Concomitant administration of VASOTEC with potassium supplements, potassium salt substitutes, or potassium-sparing diuretics may lead to increases of serum potassium (see 
 PRECAUTIONS 
 ). 

 Dosage Adjustment in Hypertensive Patients with Renal Impairment 

 The usual dose of enalapril is recommended for patients with a creatinine clearance more than 30 mL/min (serum creatinine of up to approximately 3 mg/dL). For patients with creatinine clearance less than or equal to 30 mL/min (serum creatinine more than or equal to 3 mg/dL), the first dose is 2.5 mg once daily. The dosage may be titrated upward until blood pressure is controlled or to a maximum of 40 mg daily. 

 Renal Status 

 Creatinine- 

 Clearance 

 mL/min 

 Initial Dose 

 mg/day 

 Normal Renal Function 

 &gt;80 mL/min 

 5 mg 

 Mild Impairment 

 ≤ 80 &gt;30 mL/min 

 5 mg 

 Moderate to Severe Impairment 

 ≤30 mL/min 

 2.5 mg 

 Dialysis Patients See 
 WARNINGS, Anaphylactoid reactions during membrane exposure 

 2.5 mg on dialysis days Dosage on nondialysis days should be adjusted depending on the blood pressure response. 

 Heart Failure 

 VASOTEC is indicated for the treatment of symptomatic heart failure, usually in combination with diuretics and digitalis. In the placebo-controlled studies that demonstrated improved survival, patients were titrated as tolerated up to 40 mg, administered in two divided doses. 
 The recommended initial dose is 2.5 mg. The recommended dosing range is 2.5 to 20 mg given twice a day. Doses should be titrated upward, as tolerated, over a period of a few days or weeks. The maximum daily dose administered in clinical trials was 40 mg in divided doses. 
 After the initial dose of VASOTEC, the patient should be observed under medical supervision for at least two hours and until blood pressure has stabilized for at least an additional hour (see 
 WARNINGS 
 and 
 PRECAUTIONS, Drug Interactions 
 ). If possible, the dose of any concomitant diuretic should be reduced which may diminish the likelihood of hypotension. The appearance of hypotension after the initial dose of VASOTEC does not preclude subsequent careful dose titration with the drug, following effective management of the hypotension. 

 Asymptomatic Left Ventricular Dysfunction 

 In the trial that demonstrated efficacy, patients were started on 2.5 mg twice daily and were titrated as tolerated to the targeted daily dose of 20 mg (in divided doses). 
 After the initial dose of VASOTEC, the patient should be observed under medical supervision for at least two hours and until blood pressure has stabilized for at least an additional hour (see 
 WARNINGS 
 and 
 PRECAUTIONS, Drug Interactions 
 ). If possible, the dose of any concomitant diuretic should be reduced which may diminish the likelihood of hypotension. The appearance of hypotension after the initial dose of VASOTEC does not preclude subsequent careful dose titration with the drug, following effective management of the hypotension. 

 Dosage Adjustment in Patients with Heart Failure and Renal Impairment or Hyponatremia 

 In patients with heart failure who have hyponatremia (serum sodium less than 130 mEq/L) or with serum creatinine greater than 1.6 mg/dL, therapy should be initiated at 2.5 mg daily under close medical supervision (see 
 DOSAGE AND ADMINISTRATION, Heart Failure 
 , 
 WARNINGS 
 and 
 PRECAUTIONS, Drug Interactions 
 ). The dose may be increased to 2.5 mg b.i.d., then 5 mg b.i.d. and higher as needed, usually at intervals of four days or more if at the time of dosage adjustment there is not excessive hypotension or significant deterioration of renal function. The maximum daily dose is 40 mg. 

 Pediatric Hypertensive Patients 

 The usual recommended starting dose is 0.08 mg/kg (up to 5 mg) once daily. Dosage should be adjusted according to blood pressure response. Doses above 0.58 mg/kg (or in excess of 40 mg) have not been studied in pediatric patients (see 
 CLINICAL PHARMACOLOGY, Clinical Pharmacology in Pediatric Patients 
 ). 
 VASOTEC is not recommended in neonates and in pediatric patients with glomerular filtration rate less than 30 mL/min/1.73 m 2 , as no data are available. 

 Preparation of Suspension (for 200 mL of a 1.0 mg/mL suspension) 

 Add 50 mL of Bicitra to a polyethylene terephthalate (PET) bottle containing ten 20 mg tablets of VASOTEC and shake for at least 2 minutes. Let concentrate stand for 60 minutes. Following the 60-minute hold time, shake the concentrate for an additional minute. Add 150 mL of Ora-Sweet SF to the concentrate in the PET bottle and shake the suspension to disperse the ingredients. The suspension should be refrigerated at 2-8°C (36-46°F) and can be stored for up to 30 days. Shake the suspension before each use.</Section>
</Text><Sentences>
<Sentence id="102" LabelDrug="Vasotec" section="34068-7">
<SentenceText>Add 50 mL of Bicitra Registered trademark of Alza Corporation to a polyethylene terephthalate ( PET ) bottle containing ten 20 mg tablets of VASOTEC and shake for at least 2 minutes .</SentenceText>
</Sentence>
<Sentence id="103" LabelDrug="Vasotec" section="34068-7">
<SentenceText>Concomitant administration of VASOTEC with potassium supplements , potassium salt substitutes , or potassium-sparing diuretics may lead to increases of serum potassium ( see PRECAUTIONS ) .</SentenceText>
<Mention id="M7" type="Trigger" span="127 11" str="may lead to"/>
<Mention id="M2" type="Precipitant" span="67 26" str="potassium salt substitutes" code="N0000175600"/>
<Mention id="M9" type="SpecificInteraction" span="139 28" str="increases of serum potassium" code="166689004: Raised serum potassium level (finding)"/>
<Mention id="M5" type="Precipitant" span="43 21" str="potassium supplements" code="N0000175600"/>
<Mention id="M8" type="Precipitant" span="99 27" str="potassium-sparing diuretics" code="N0000175418"/>
<Interaction id="I1" type="Pharmacodynamic interaction" trigger="M7" precipitant="M2" effect="M9"/>
<Interaction id="I2" type="Pharmacodynamic interaction" trigger="M7" precipitant="M5" effect="M9"/>
<Interaction id="I3" type="Pharmacodynamic interaction" trigger="M7" precipitant="M8" effect="M9"/>
</Sentence>
<Sentence id="103" LabelDrug="Vasotec" section="34068-7">
<SentenceText>Concomitant administration of VASOTEC with potassium supplements , potassium salt substitutes , or potassium-sparing diuretics may lead to increases of serum potassium ( see PRECAUTIONS ) .</SentenceText>
<Mention id="M16" type="Trigger" span="127 11" str="may lead to"/>
<Mention id="M11" type="Precipitant" span="67 26" str="potassium salt substitutes" code="N0000175600"/>
<Mention id="M18" type="SpecificInteraction" span="139 28" str="increases of serum potassium" code="166689004: Raised serum potassium level (finding)"/>
<Mention id="M14" type="Precipitant" span="43 21" str="potassium supplements" code="N0000175600"/>
<Mention id="M17" type="Precipitant" span="99 27" str="potassium-sparing diuretics" code="N0000175418"/>
<Interaction id="I4" type="Pharmacodynamic interaction" trigger="M16" precipitant="M11" effect="M18"/>
<Interaction id="I5" type="Pharmacodynamic interaction" trigger="M16" precipitant="M14" effect="M18"/>
<Interaction id="I6" type="Pharmacodynamic interaction" trigger="M16" precipitant="M17" effect="M18"/>
</Sentence>
<Sentence id="103" LabelDrug="Vasotec" section="34068-7">
<SentenceText>Concomitant administration of VASOTEC with potassium supplements , potassium salt substitutes , or potassium-sparing diuretics may lead to increases of serum potassium ( see PRECAUTIONS ) .</SentenceText>
<Mention id="M25" type="Trigger" span="127 11" str="may lead to"/>
<Mention id="M20" type="Precipitant" span="67 26" str="potassium salt substitutes" code="N0000175600"/>
<Mention id="M27" type="SpecificInteraction" span="139 28" str="increases of serum potassium" code="166689004: Raised serum potassium level (finding)"/>
<Mention id="M23" type="Precipitant" span="43 21" str="potassium supplements" code="N0000175600"/>
<Mention id="M26" type="Precipitant" span="99 27" str="potassium-sparing diuretics" code="N0000175418"/>
<Interaction id="I7" type="Pharmacodynamic interaction" trigger="M25" precipitant="M20" effect="M27"/>
<Interaction id="I8" type="Pharmacodynamic interaction" trigger="M25" precipitant="M23" effect="M27"/>
<Interaction id="I9" type="Pharmacodynamic interaction" trigger="M25" precipitant="M26" effect="M27"/>
</Sentence>
<Sentence id="104" LabelDrug="Vasotec" section="34068-7">
<SentenceText>If blood pressure is not controlled with VASOTEC alone , a diuretic may be added .</SentenceText>
</Sentence>
<Sentence id="105" LabelDrug="Vasotec" section="34068-7">
<SentenceText>In patients who are currently being treated with a diuretic , symptomatic hypotension occasionally may occur following the initial dose of VASOTEC .</SentenceText>
<Mention id="M28" type="Trigger" span="99 9" str="may occur"/>
<Mention id="M29" type="Precipitant" span="51 8" str="diuretic" code="N0000029125"/>
<Mention id="M30" type="SpecificInteraction" span="62 23" str="symptomatic hypotension" code="45007003: Low blood pressure (disorder)"/>
<Interaction id="I10" type="Pharmacodynamic interaction" trigger="M28" precipitant="M29" effect="M30"/>
</Sentence>
<Sentence id="106" LabelDrug="Vasotec" section="34068-7">
<SentenceText>The diuretic should , if possible , be discontinued for two to three days before beginning therapy with VASOTEC to reduce the likelihood of hypotension ( see WARNINGS ) .</SentenceText>
<Mention id="M31" type="Trigger" span="39 12;112 24" str="discontinued | to reduce the likelihood"/>
<Mention id="M32" type="Precipitant" span="4 8" str="diuretic" code="N0000029125"/>
<Mention id="M33" type="SpecificInteraction" span="140 11" str="hypotension" code="45007003: Low blood pressure (disorder)"/>
<Interaction id="I11" type="Pharmacodynamic interaction" trigger="M31" precipitant="M32" effect="M33"/>
</Sentence>
<Sentence id="107" LabelDrug="Vasotec" section="34068-7">
<SentenceText>VASOTEC is indicated for the treatment of symptomatic heart failure , usually in combination with diuretics and digitalis .</SentenceText>
</Sentence>
<Sentence id="108" LabelDrug="Vasotec" section="34070-3">
<SentenceText>Do not administer VASOTEC within 36 hours of switching to or from sacubitril/valsartan , a neprilysin inhibitor ( see WARNINGS ) .</SentenceText>
<Mention id="M36" type="Trigger" span="0 17" str="Do not administer"/>
<Mention id="M35" type="Precipitant" span="91 20" str="neprilysin inhibitor" code="N0000191728"/>
<Mention id="M37" type="Precipitant" span="66 20" str="sacubitril/valsartan" code="N0000191740"/>
<Interaction id="I12" type="Unspecified interaction" trigger="M36" precipitant="M35"/>
<Interaction id="I13" type="Unspecified interaction" trigger="M36" precipitant="M37"/>
</Sentence>
<Sentence id="108" LabelDrug="Vasotec" section="34070-3">
<SentenceText>Do not administer VASOTEC within 36 hours of switching to or from sacubitril/valsartan , a neprilysin inhibitor ( see WARNINGS ) .</SentenceText>
<Mention id="M40" type="Trigger" span="0 17" str="Do not administer"/>
<Mention id="M39" type="Precipitant" span="91 20" str="neprilysin inhibitor" code="N0000191728"/>
<Mention id="M41" type="Precipitant" span="66 20" str="sacubitril/valsartan" code="N0000191740"/>
<Interaction id="I14" type="Unspecified interaction" trigger="M40" precipitant="M39"/>
<Interaction id="I15" type="Unspecified interaction" trigger="M40" precipitant="M41"/>
</Sentence>
<Sentence id="109" LabelDrug="Vasotec" section="34070-3">
<SentenceText>Do not coadminister aliskiren with VASOTEC in patients with diabetes ( see PRECAUTIONS , Drug Interactions ) .</SentenceText>
<Mention id="M42" type="Trigger" span="0 19" str="Do not coadminister"/>
<Mention id="M43" type="Precipitant" span="20 9" str="aliskiren" code="N0000176084"/>
<Interaction id="I16" type="Unspecified interaction" trigger="M42" precipitant="M43"/>
</Sentence>
<Sentence id="110" LabelDrug="Vasotec" section="34070-3">
<SentenceText>VASOTEC is contraindicated in combination with a neprilysin inhibitor ( e.g. , sacubitril ) .</SentenceText>
<Mention id="M46" type="Trigger" span="11 15" str="contraindicated"/>
<Mention id="M45" type="Precipitant" span="49 20" str="neprilysin inhibitor" code="N0000191728"/>
<Mention id="M47" type="Precipitant" span="79 10" str="sacubitril" code="N0000191735"/>
<Interaction id="I17" type="Unspecified interaction" trigger="M46" precipitant="M45"/>
<Interaction id="I18" type="Unspecified interaction" trigger="M46" precipitant="M47"/>
</Sentence>
<Sentence id="110" LabelDrug="Vasotec" section="34070-3">
<SentenceText>VASOTEC is contraindicated in combination with a neprilysin inhibitor ( e.g. , sacubitril ) .</SentenceText>
<Mention id="M50" type="Trigger" span="11 15" str="contraindicated"/>
<Mention id="M49" type="Precipitant" span="49 20" str="neprilysin inhibitor" code="N0000191728"/>
<Mention id="M51" type="Precipitant" span="79 10" str="sacubitril" code="N0000191735"/>
<Interaction id="I19" type="Unspecified interaction" trigger="M50" precipitant="M49"/>
<Interaction id="I20" type="Unspecified interaction" trigger="M50" precipitant="M51"/>
</Sentence>
<Sentence id="111" LabelDrug="Vasotec" section="34070-3">
<SentenceText>VASOTEC is contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous treatment with an angiotensin converting enzyme inhibitor and in patients with hereditary or idiopathic angioedema .</SentenceText>
</Sentence>
<Sentence id="112" LabelDrug="Vasotec" section="34071-1">
<SentenceText>Angioedema of the face , extremities , lips , tongue , glottis and/or larynx has been reported in patients treated with angiotensin converting enzyme inhibitors , including VASOTEC .</SentenceText>
</Sentence>
<Sentence id="113" LabelDrug="Vasotec" section="34071-1">
<SentenceText>If symptomatic hypotension develops , a dose reduction or discontinuation of VASOTEC or concomitant diuretic may be necessary .</SentenceText>
<Mention id="M52" type="Trigger" span="40 14" str="dose reduction "/>
<Mention id="M53" type="Trigger" span="58 15" str=" discontinuation"/>
<Mention id="M54" type="Precipitant" span="100 8" str="diuretic" code="N0000029125"/>
<Mention id="M55" type="SpecificInteraction" span="3 23" str="symptomatic hypotension" code="45007003: Low blood pressure (disorder)"/>
<Interaction id="I21" type="Pharmacodynamic interaction" trigger="M52;M53" precipitant="M54" effect="M55"/>
</Sentence>
<Sentence id="114" LabelDrug="Vasotec" section="34071-1">
<SentenceText>In patients at risk for excessive hypotension , therapy should be started under very close medical supervision and such patients should be followed closely for the first two weeks of treatment and whenever the dose of enalapril and/or diuretic is increased .</SentenceText>
<Mention id="M56" type="Trigger" span="85 5;99 11" str="close | supervision "/>
<Mention id="M57" type="Trigger" span="129 18" str=" should be followed"/>
<Mention id="M58" type="Precipitant" span="235 8" str="diuretic" code="N0000029125"/>
<Interaction id="I22" type="Unspecified interaction" trigger="M56;M57" precipitant="M58"/>
</Sentence>
<Sentence id="115" LabelDrug="Vasotec" section="34071-1">
<SentenceText>It may be advisable to eliminate the diuretic ( except in patients with heart failure ) , reduce the diuretic dose or increase salt intake cautiously before initiating therapy with VASOTEC in patients at risk for excessive hypotension who are able to tolerate such adjustments ( see PRECAUTIONS , Drug Interactions and ADVERSE REACTIONS ) .</SentenceText>
<Mention id="M59" type="Trigger" span="23 9" str="eliminate "/>
<Mention id="M60" type="Trigger" span="90 6;110 4" str=" reduce | dose"/>
<Mention id="M61" type="Precipitant" span="37 8" str="diuretic" code="N0000029125"/>
<Interaction id="I23" type="Unspecified interaction" trigger="M59;M60" precipitant="M61"/>
</Sentence>
<Sentence id="116" LabelDrug="Vasotec" section="34071-1">
<SentenceText>Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of eicosanoids and polypeptides , including endogenous bradykinin , patients receiving ACE inhibitors ( including VASOTEC ) may be subject to a variety of adverse reactions , some of them serious .</SentenceText>
<Mention id="M66" type="Trigger" span="60 6;71 10" str="affect | metabolism"/>
<Mention id="M63" type="Precipitant" span="85 11" str="eicosanoids" code="n0000008271"/>
<Mention id="M65" type="Precipitant" span="126 21" str="endogenous bradykinin" code="NO MAP"/>
<Mention id="M67" type="Precipitant" span="101 12" str="polypeptides" code="NO MAP"/>
<Interaction id="I24" type="Unspecified interaction" trigger="M66" precipitant="M63"/>
<Interaction id="I25" type="Unspecified interaction" trigger="M66" precipitant="M65"/>
<Interaction id="I26" type="Unspecified interaction" trigger="M66" precipitant="M67"/>
</Sentence>
<Sentence id="116" LabelDrug="Vasotec" section="34071-1">
<SentenceText>Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of eicosanoids and polypeptides , including endogenous bradykinin , patients receiving ACE inhibitors ( including VASOTEC ) may be subject to a variety of adverse reactions , some of them serious .</SentenceText>
<Mention id="M72" type="Trigger" span="60 6;71 10" str="affect | metabolism"/>
<Mention id="M69" type="Precipitant" span="85 11" str="eicosanoids" code="n0000008271"/>
<Mention id="M71" type="Precipitant" span="126 21" str="endogenous bradykinin" code="NO MAP"/>
<Mention id="M73" type="Precipitant" span="101 12" str="polypeptides" code="NO MAP"/>
<Interaction id="I27" type="Unspecified interaction" trigger="M72" precipitant="M69"/>
<Interaction id="I28" type="Unspecified interaction" trigger="M72" precipitant="M71"/>
<Interaction id="I29" type="Unspecified interaction" trigger="M72" precipitant="M73"/>
</Sentence>
<Sentence id="116" LabelDrug="Vasotec" section="34071-1">
<SentenceText>Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of eicosanoids and polypeptides , including endogenous bradykinin , patients receiving ACE inhibitors ( including VASOTEC ) may be subject to a variety of adverse reactions , some of them serious .</SentenceText>
<Mention id="M78" type="Trigger" span="60 6;71 10" str="affect | metabolism"/>
<Mention id="M75" type="Precipitant" span="85 11" str="eicosanoids" code="n0000008271"/>
<Mention id="M77" type="Precipitant" span="126 21" str="endogenous bradykinin" code="NO MAP"/>
<Mention id="M79" type="Precipitant" span="101 12" str="polypeptides" code="NO MAP"/>
<Interaction id="I30" type="Unspecified interaction" trigger="M78" precipitant="M75"/>
<Interaction id="I31" type="Unspecified interaction" trigger="M78" precipitant="M77"/>
<Interaction id="I32" type="Unspecified interaction" trigger="M78" precipitant="M79"/>
</Sentence>
<Sentence id="117" LabelDrug="Vasotec" section="34073-7">
<SentenceText>(see WARNINGS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.</SentenceText>
<Mention id="M90" type="Trigger" span="124 15" str="increased risks"/>
<Mention id="M81" type="Precipitant" span="76 14" str="ACE inhibitors" code="N0000029130"/>
<Mention id="M92" type="SpecificInteraction" span="143 11" str="hypotension " code="45007003: Low blood pressure (disorder)"/>
<Mention id="M93" type="SpecificInteraction" span="156 12" str=" hyperkalemia " code=" 14140009: Hyperkalemia (disorder)"/>
<Mention id="M94" type="SpecificInteraction" span="174 57" str=" changes in renal function (including acute renal failure)" code=" 39539005: Abnormal renal function (finding)"/>
<Mention id="M86" type="Precipitant" span="95 9" str="aliskiren" code="N0000176084"/>
<Mention id="M91" type="Precipitant" span="45 29" str="angiotensin receptor blockers" code="N0000000070"/>
<Interaction id="I33" type="Pharmacodynamic interaction" trigger="M90" precipitant="M81" effect="M92;M93;M94"/>
<Interaction id="I34" type="Pharmacodynamic interaction" trigger="M90" precipitant="M86" effect="M92;M93;M94"/>
<Interaction id="I35" type="Pharmacodynamic interaction" trigger="M90" precipitant="M91" effect="M92;M93;M94"/>
</Sentence>
<Sentence id="117" LabelDrug="Vasotec" section="34073-7">
<SentenceText>(see WARNINGS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.</SentenceText>
<Mention id="M105" type="Trigger" span="124 15" str="increased risks"/>
<Mention id="M96" type="Precipitant" span="76 14" str="ACE inhibitors" code="N0000029130"/>
<Mention id="M107" type="SpecificInteraction" span="143 11" str="hypotension " code="45007003: Low blood pressure (disorder)"/>
<Mention id="M108" type="SpecificInteraction" span="156 12" str=" hyperkalemia " code=" 14140009: Hyperkalemia (disorder)"/>
<Mention id="M109" type="SpecificInteraction" span="174 57" str=" changes in renal function (including acute renal failure)" code=" 39539005: Abnormal renal function (finding)"/>
<Mention id="M101" type="Precipitant" span="95 9" str="aliskiren" code="N0000176084"/>
<Mention id="M106" type="Precipitant" span="45 29" str="angiotensin receptor blockers" code="N0000000070"/>
<Interaction id="I36" type="Pharmacodynamic interaction" trigger="M105" precipitant="M96" effect="M107;M108;M109"/>
<Interaction id="I37" type="Pharmacodynamic interaction" trigger="M105" precipitant="M101" effect="M107;M108;M109"/>
<Interaction id="I38" type="Pharmacodynamic interaction" trigger="M105" precipitant="M106" effect="M107;M108;M109"/>
</Sentence>
<Sentence id="117" LabelDrug="Vasotec" section="34073-7">
<SentenceText>(see WARNINGS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.</SentenceText>
<Mention id="M120" type="Trigger" span="124 15" str="increased risks"/>
<Mention id="M111" type="Precipitant" span="76 14" str="ACE inhibitors" code="N0000029130"/>
<Mention id="M122" type="SpecificInteraction" span="143 11" str="hypotension " code="45007003: Low blood pressure (disorder)"/>
<Mention id="M123" type="SpecificInteraction" span="156 12" str=" hyperkalemia " code=" 14140009: Hyperkalemia (disorder)"/>
<Mention id="M124" type="SpecificInteraction" span="174 57" str=" changes in renal function (including acute renal failure)" code=" 39539005: Abnormal renal function (finding)"/>
<Mention id="M116" type="Precipitant" span="95 9" str="aliskiren" code="N0000176084"/>
<Mention id="M121" type="Precipitant" span="45 29" str="angiotensin receptor blockers" code="N0000000070"/>
<Interaction id="I39" type="Pharmacodynamic interaction" trigger="M120" precipitant="M111" effect="M122;M123;M124"/>
<Interaction id="I40" type="Pharmacodynamic interaction" trigger="M120" precipitant="M116" effect="M122;M123;M124"/>
<Interaction id="I41" type="Pharmacodynamic interaction" trigger="M120" precipitant="M121" effect="M122;M123;M124"/>
</Sentence>
<Sentence id="118" LabelDrug="Vasotec" section="34073-7">
<SentenceText>Agents Causing Renin Release: The antihypertensive effect of VASOTEC is augmented by antihypertensive agents that cause renin release (e.g., diuretics).</SentenceText>
<Mention id="M131" type="Trigger" span="72 9" str="augmented"/>
<Mention id="M126" type="Precipitant" span="0 28" str="Agents Causing Renin Release" code="NO MAP"/>
<Mention id="M133" type="SpecificInteraction" span="34 23" str="antihypertensive effect" code="163036009: On examination - blood pressure decreased (finding)"/>
<Mention id="M129" type="Precipitant" span="85 48" str="antihypertensive agents that cause renin release" code="NO MAP"/>
<Mention id="M132" type="Precipitant" span="141 9" str="diuretics" code="N0000029125"/>
<Interaction id="I42" type="Pharmacodynamic interaction" trigger="M131" precipitant="M126" effect="M133"/>
<Interaction id="I43" type="Pharmacodynamic interaction" trigger="M131" precipitant="M129" effect="M133"/>
<Interaction id="I44" type="Pharmacodynamic interaction" trigger="M131" precipitant="M132" effect="M133"/>
</Sentence>
<Sentence id="118" LabelDrug="Vasotec" section="34073-7">
<SentenceText>Agents Causing Renin Release: The antihypertensive effect of VASOTEC is augmented by antihypertensive agents that cause renin release (e.g., diuretics).</SentenceText>
<Mention id="M140" type="Trigger" span="72 9" str="augmented"/>
<Mention id="M135" type="Precipitant" span="0 28" str="Agents Causing Renin Release" code="NO MAP"/>
<Mention id="M142" type="SpecificInteraction" span="34 23" str="antihypertensive effect" code="163036009: On examination - blood pressure decreased (finding)"/>
<Mention id="M138" type="Precipitant" span="85 48" str="antihypertensive agents that cause renin release" code="NO MAP"/>
<Mention id="M141" type="Precipitant" span="141 9" str="diuretics" code="N0000029125"/>
<Interaction id="I45" type="Pharmacodynamic interaction" trigger="M140" precipitant="M135" effect="M142"/>
<Interaction id="I46" type="Pharmacodynamic interaction" trigger="M140" precipitant="M138" effect="M142"/>
<Interaction id="I47" type="Pharmacodynamic interaction" trigger="M140" precipitant="M141" effect="M142"/>
</Sentence>
<Sentence id="118" LabelDrug="Vasotec" section="34073-7">
<SentenceText>Agents Causing Renin Release: The antihypertensive effect of VASOTEC is augmented by antihypertensive agents that cause renin release (e.g., diuretics).</SentenceText>
<Mention id="M149" type="Trigger" span="72 9" str="augmented"/>
<Mention id="M144" type="Precipitant" span="0 28" str="Agents Causing Renin Release" code="NO MAP"/>
<Mention id="M151" type="SpecificInteraction" span="34 23" str="antihypertensive effect" code="163036009: On examination - blood pressure decreased (finding)"/>
<Mention id="M147" type="Precipitant" span="85 48" str="antihypertensive agents that cause renin release" code="NO MAP"/>
<Mention id="M150" type="Precipitant" span="141 9" str="diuretics" code="N0000029125"/>
<Interaction id="I48" type="Pharmacodynamic interaction" trigger="M149" precipitant="M144" effect="M151"/>
<Interaction id="I49" type="Pharmacodynamic interaction" trigger="M149" precipitant="M147" effect="M151"/>
<Interaction id="I50" type="Pharmacodynamic interaction" trigger="M149" precipitant="M150" effect="M151"/>
</Sentence>
<Sentence id="119" LabelDrug="Vasotec" section="34073-7">
<SentenceText>Agents Increasing Serum Potassium: VASOTEC attenuates potassium loss caused by thiazide-type diuretics.</SentenceText>
<Mention id="M154" type="SpecificInteraction" span="43 25" str="attenuates potassium loss" code="NO MAP"/>
<Mention id="M153" type="Precipitant" span="79 23" str="thiazide-type diuretics" code="N0000029126"/>
<Interaction id="I51" type="Pharmacodynamic interaction" trigger="M154" precipitant="M153" effect="M154"/>
</Sentence>
<Sentence id="120" LabelDrug="Vasotec" section="34073-7">
<SentenceText>Drug Interactions Neprilysin Inhibitors: Patients taking concomitant neprilysin inhibitors may be at increased risk for angioedema.</SentenceText>
<Mention id="M155" type="Trigger" span="101 14" str="increased risk"/>
<Mention id="M156" type="Precipitant" span="69 21" str="neprilysin inhibitors" code="NO MAP"/>
<Mention id="M157" type="SpecificInteraction" span="120 10" str="angioedema" code="41291007: Angioedema (disorder)"/>
<Interaction id="I52" type="Pharmacodynamic interaction" trigger="M155" precipitant="M156" effect="M157"/>
</Sentence>
<Sentence id="121" LabelDrug="Vasotec" section="34073-7">
<SentenceText>Gold: Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including VASOTEC. mTOR (mammalian target of rapamycin) inhibitors: Patients receiving coadministration of ACE inhibitor and mTOR inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema (see WARNINGS).</SentenceText>
<Mention id="M175" type="Trigger" span="429 14" str="increased risk"/>
<Mention id="M159" type="Precipitant" span="399 10" str="everolimus" code="N0000178379"/>
<Mention id="M177" type="SpecificInteraction" span="448 10" str="angioedema" code="41291007: Angioedema (disorder)"/>
<Mention id="M162" type="Precipitant" span="246 4;283 10" str="mTOR | inhibitors" code="n0000175624"/>
<Mention id="M165" type="Precipitant" span="377 9" str="sirolimus" code="N0000006605"/>
<Mention id="M167" type="Trigger" span="16 9" str="reactions "/>
<Mention id="M168" type="Trigger" span="27 8" str=" symptoms"/>
<Mention id="M169" type="Precipitant" span="166 21" str="sodium aurothiomalate" code="N0000006015"/>
<Mention id="M170" type="SpecificInteraction" span="6 19" str="Nitritoid reactions " code="426711003: Nitritoid reaction (disorder)"/>
<Mention id="M171" type="SpecificInteraction" span="44 15" str=" facial flushing " code=" 238810007: Flushing (disorder)"/>
<Mention id="M172" type="SpecificInteraction" span="61 6" str=" nausea " code="  422587007: Nausea (finding)"/>
<Mention id="M173" type="SpecificInteraction" span="69 8" str=" vomiting " code=" 422400008: Vomiting (disorder)"/>
<Mention id="M174" type="SpecificInteraction" span="82 11" str=" hypotension" code=" 45007003: Low blood pressure (disorder)"/>
<Mention id="M176" type="Precipitant" span="374 12" str="temsirolimus" code="N0000176108"/>
<Interaction id="I53" type="Pharmacodynamic interaction" trigger="M175" precipitant="M159" effect="M177"/>
<Interaction id="I54" type="Pharmacodynamic interaction" trigger="M175" precipitant="M162" effect="M177"/>
<Interaction id="I55" type="Pharmacodynamic interaction" trigger="M175" precipitant="M165" effect="M177"/>
<Interaction id="I56" type="Pharmacodynamic interaction" trigger="M167;M168" precipitant="M169" effect="M170;M171;M172;M173;M174"/>
<Interaction id="I57" type="Pharmacodynamic interaction" trigger="M175" precipitant="M176" effect="M177"/>
</Sentence>
<Sentence id="121" LabelDrug="Vasotec" section="34073-7">
<SentenceText>Gold: Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including VASOTEC. mTOR (mammalian target of rapamycin) inhibitors: Patients receiving coadministration of ACE inhibitor and mTOR inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema (see WARNINGS).</SentenceText>
<Mention id="M195" type="Trigger" span="429 14" str="increased risk"/>
<Mention id="M179" type="Precipitant" span="399 10" str="everolimus" code="N0000178379"/>
<Mention id="M197" type="SpecificInteraction" span="448 10" str="angioedema" code="41291007: Angioedema (disorder)"/>
<Mention id="M182" type="Precipitant" span="246 4;283 10" str="mTOR | inhibitors" code="n0000175624"/>
<Mention id="M185" type="Precipitant" span="377 9" str="sirolimus" code="N0000006605"/>
<Mention id="M187" type="Trigger" span="16 9" str="reactions "/>
<Mention id="M188" type="Trigger" span="27 8" str=" symptoms"/>
<Mention id="M189" type="Precipitant" span="166 21" str="sodium aurothiomalate" code="N0000006015"/>
<Mention id="M190" type="SpecificInteraction" span="6 19" str="Nitritoid reactions " code="426711003: Nitritoid reaction (disorder)"/>
<Mention id="M191" type="SpecificInteraction" span="44 15" str=" facial flushing " code=" 238810007: Flushing (disorder)"/>
<Mention id="M192" type="SpecificInteraction" span="61 6" str=" nausea " code="  422587007: Nausea (finding)"/>
<Mention id="M193" type="SpecificInteraction" span="69 8" str=" vomiting " code=" 422400008: Vomiting (disorder)"/>
<Mention id="M194" type="SpecificInteraction" span="82 11" str=" hypotension" code=" 45007003: Low blood pressure (disorder)"/>
<Mention id="M196" type="Precipitant" span="374 12" str="temsirolimus" code="N0000176108"/>
<Interaction id="I58" type="Pharmacodynamic interaction" trigger="M195" precipitant="M179" effect="M197"/>
<Interaction id="I59" type="Pharmacodynamic interaction" trigger="M195" precipitant="M182" effect="M197"/>
<Interaction id="I60" type="Pharmacodynamic interaction" trigger="M195" precipitant="M185" effect="M197"/>
<Interaction id="I61" type="Pharmacodynamic interaction" trigger="M187;M188" precipitant="M189" effect="M190;M191;M192;M193;M194"/>
<Interaction id="I62" type="Pharmacodynamic interaction" trigger="M195" precipitant="M196" effect="M197"/>
</Sentence>
<Sentence id="121" LabelDrug="Vasotec" section="34073-7">
<SentenceText>Gold: Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including VASOTEC. mTOR (mammalian target of rapamycin) inhibitors: Patients receiving coadministration of ACE inhibitor and mTOR inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema (see WARNINGS).</SentenceText>
<Mention id="M215" type="Trigger" span="429 14" str="increased risk"/>
<Mention id="M199" type="Precipitant" span="399 10" str="everolimus" code="N0000178379"/>
<Mention id="M217" type="SpecificInteraction" span="448 10" str="angioedema" code="41291007: Angioedema (disorder)"/>
<Mention id="M202" type="Precipitant" span="246 4;283 10" str="mTOR | inhibitors" code="n0000175624"/>
<Mention id="M205" type="Precipitant" span="377 9" str="sirolimus" code="N0000006605"/>
<Mention id="M207" type="Trigger" span="16 9" str="reactions "/>
<Mention id="M208" type="Trigger" span="27 8" str=" symptoms"/>
<Mention id="M209" type="Precipitant" span="166 21" str="sodium aurothiomalate" code="N0000006015"/>
<Mention id="M210" type="SpecificInteraction" span="6 19" str="Nitritoid reactions " code="426711003: Nitritoid reaction (disorder)"/>
<Mention id="M211" type="SpecificInteraction" span="44 15" str=" facial flushing " code=" 238810007: Flushing (disorder)"/>
<Mention id="M212" type="SpecificInteraction" span="61 6" str=" nausea " code="  422587007: Nausea (finding)"/>
<Mention id="M213" type="SpecificInteraction" span="69 8" str=" vomiting " code=" 422400008: Vomiting (disorder)"/>
<Mention id="M214" type="SpecificInteraction" span="82 11" str=" hypotension" code=" 45007003: Low blood pressure (disorder)"/>
<Mention id="M216" type="Precipitant" span="374 12" str="temsirolimus" code="N0000176108"/>
<Interaction id="I63" type="Pharmacodynamic interaction" trigger="M215" precipitant="M199" effect="M217"/>
<Interaction id="I64" type="Pharmacodynamic interaction" trigger="M215" precipitant="M202" effect="M217"/>
<Interaction id="I65" type="Pharmacodynamic interaction" trigger="M215" precipitant="M205" effect="M217"/>
<Interaction id="I66" type="Pharmacodynamic interaction" trigger="M207;M208" precipitant="M209" effect="M210;M211;M212;M213;M214"/>
<Interaction id="I67" type="Pharmacodynamic interaction" trigger="M215" precipitant="M216" effect="M217"/>
</Sentence>
<Sentence id="121" LabelDrug="Vasotec" section="34073-7">
<SentenceText>Gold: Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including VASOTEC. mTOR (mammalian target of rapamycin) inhibitors: Patients receiving coadministration of ACE inhibitor and mTOR inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema (see WARNINGS).</SentenceText>
<Mention id="M235" type="Trigger" span="429 14" str="increased risk"/>
<Mention id="M219" type="Precipitant" span="399 10" str="everolimus" code="N0000178379"/>
<Mention id="M237" type="SpecificInteraction" span="448 10" str="angioedema" code="41291007: Angioedema (disorder)"/>
<Mention id="M222" type="Precipitant" span="246 4;283 10" str="mTOR | inhibitors" code="n0000175624"/>
<Mention id="M225" type="Precipitant" span="377 9" str="sirolimus" code="N0000006605"/>
<Mention id="M227" type="Trigger" span="16 9" str="reactions "/>
<Mention id="M228" type="Trigger" span="27 8" str=" symptoms"/>
<Mention id="M229" type="Precipitant" span="166 21" str="sodium aurothiomalate" code="N0000006015"/>
<Mention id="M230" type="SpecificInteraction" span="6 19" str="Nitritoid reactions " code="426711003: Nitritoid reaction (disorder)"/>
<Mention id="M231" type="SpecificInteraction" span="44 15" str=" facial flushing " code=" 238810007: Flushing (disorder)"/>
<Mention id="M232" type="SpecificInteraction" span="61 6" str=" nausea " code="  422587007: Nausea (finding)"/>
<Mention id="M233" type="SpecificInteraction" span="69 8" str=" vomiting " code=" 422400008: Vomiting (disorder)"/>
<Mention id="M234" type="SpecificInteraction" span="82 11" str=" hypotension" code=" 45007003: Low blood pressure (disorder)"/>
<Mention id="M236" type="Precipitant" span="374 12" str="temsirolimus" code="N0000176108"/>
<Interaction id="I68" type="Pharmacodynamic interaction" trigger="M235" precipitant="M219" effect="M237"/>
<Interaction id="I69" type="Pharmacodynamic interaction" trigger="M235" precipitant="M222" effect="M237"/>
<Interaction id="I70" type="Pharmacodynamic interaction" trigger="M235" precipitant="M225" effect="M237"/>
<Interaction id="I71" type="Pharmacodynamic interaction" trigger="M227;M228" precipitant="M229" effect="M230;M231;M232;M233;M234"/>
<Interaction id="I72" type="Pharmacodynamic interaction" trigger="M235" precipitant="M236" effect="M237"/>
</Sentence>
<Sentence id="121" LabelDrug="Vasotec" section="34073-7">
<SentenceText>Gold: Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including VASOTEC. mTOR (mammalian target of rapamycin) inhibitors: Patients receiving coadministration of ACE inhibitor and mTOR inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema (see WARNINGS).</SentenceText>
<Mention id="M255" type="Trigger" span="429 14" str="increased risk"/>
<Mention id="M239" type="Precipitant" span="399 10" str="everolimus" code="N0000178379"/>
<Mention id="M257" type="SpecificInteraction" span="448 10" str="angioedema" code="41291007: Angioedema (disorder)"/>
<Mention id="M242" type="Precipitant" span="246 4;283 10" str="mTOR | inhibitors" code="n0000175624"/>
<Mention id="M245" type="Precipitant" span="377 9" str="sirolimus" code="N0000006605"/>
<Mention id="M247" type="Trigger" span="16 9" str="reactions "/>
<Mention id="M248" type="Trigger" span="27 8" str=" symptoms"/>
<Mention id="M249" type="Precipitant" span="166 21" str="sodium aurothiomalate" code="N0000006015"/>
<Mention id="M250" type="SpecificInteraction" span="6 19" str="Nitritoid reactions " code="426711003: Nitritoid reaction (disorder)"/>
<Mention id="M251" type="SpecificInteraction" span="44 15" str=" facial flushing " code=" 238810007: Flushing (disorder)"/>
<Mention id="M252" type="SpecificInteraction" span="61 6" str=" nausea " code="  422587007: Nausea (finding)"/>
<Mention id="M253" type="SpecificInteraction" span="69 8" str=" vomiting " code=" 422400008: Vomiting (disorder)"/>
<Mention id="M254" type="SpecificInteraction" span="82 11" str=" hypotension" code=" 45007003: Low blood pressure (disorder)"/>
<Mention id="M256" type="Precipitant" span="374 12" str="temsirolimus" code="N0000176108"/>
<Interaction id="I73" type="Pharmacodynamic interaction" trigger="M255" precipitant="M239" effect="M257"/>
<Interaction id="I74" type="Pharmacodynamic interaction" trigger="M255" precipitant="M242" effect="M257"/>
<Interaction id="I75" type="Pharmacodynamic interaction" trigger="M255" precipitant="M245" effect="M257"/>
<Interaction id="I76" type="Pharmacodynamic interaction" trigger="M247;M248" precipitant="M249" effect="M250;M251;M252;M253;M254"/>
<Interaction id="I77" type="Pharmacodynamic interaction" trigger="M255" precipitant="M256" effect="M257"/>
</Sentence>
<Sentence id="122" LabelDrug="Vasotec" section="34073-7">
<SentenceText>However, reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors.</SentenceText>
<Mention id="M258" type="Trigger" span="41 8;71 6" str="diminish | effect"/>
<Mention id="M259" type="Precipitant" span="30 6" str="NSAIDs" code="N0000175722"/>
<Mention id="M260" type="SpecificInteraction" span="41 8;54 23" str="diminish | antihypertensive effect" code="NO MAP"/>
<Interaction id="I78" type="Pharmacodynamic interaction" trigger="M258" precipitant="M259" effect="M260"/>
</Sentence>
<Sentence id="123" LabelDrug="Vasotec" section="34073-7">
<SentenceText>Hypotension  Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril.</SentenceText>
<Mention id="M261" type="Trigger" span="136 3;153 10" str="may | experience"/>
<Mention id="M262" type="Precipitant" span="55 9" str="diuretics" code="N0000029125"/>
<Mention id="M263" type="SpecificInteraction" span="167 37" str="excessive reduction of blood pressure" code="12763006: Finding of decreased blood pressure (finding)"/>
<Interaction id="I79" type="Pharmacodynamic interaction" trigger="M261" precipitant="M262" effect="M263"/>
</Sentence>
<Sentence id="124" LabelDrug="Vasotec" section="34073-7">
<SentenceText>If it is necessary to continue the diuretic, provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour (see WARNINGS and DOSAGE AND ADMINISTRATION ).</SentenceText>
<Mention id="M264" type="Trigger" span="67 11" str="supervision"/>
<Mention id="M265" type="Precipitant" span="35 8" str="diuretic" code="N0000029125"/>
<Interaction id="I80" type="Unspecified interaction" trigger="M264" precipitant="M265"/>
</Sentence>
<Sentence id="125" LabelDrug="Vasotec" section="34073-7">
<SentenceText>In general, avoid combined use of RAS inhibitors.</SentenceText>
<Mention id="M266" type="Trigger" span="12 5" str="avoid"/>
<Mention id="M267" type="Precipitant" span="34 14" str="RAS inhibitors" code="NO MAP"/>
<Interaction id="I81" type="Unspecified interaction" trigger="M266" precipitant="M267"/>
</Sentence>
<Sentence id="126" LabelDrug="Vasotec" section="34073-7">
<SentenceText>Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.</SentenceText>
<Mention id="M268" type="Trigger" span="17 8" str="toxicity"/>
<Mention id="M269" type="Precipitant" span="66 7" str="lithium" code="N0000147892"/>
<Interaction id="I82" type="Pharmacokinetic interaction" trigger="M268" precipitant="M269" effect="C54357"/>
</Sentence>
<Sentence id="127" LabelDrug="Vasotec" section="34073-7">
<SentenceText>Most patients receiving the combination of two RAS inhibitors do not obtain any additional benefit compared to monotherapy.</SentenceText>
</Sentence>
<Sentence id="128" LabelDrug="Vasotec" section="34073-7">
<SentenceText>Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors): In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including enalapril, may result in deterioration of renal function, including possible acute renal failure.</SentenceText>
<Mention id="M274" type="Trigger" span="339 9" str="result in"/>
<Mention id="M271" type="Precipitant" span="247 6" str="NSAIDs" code="N0000175722"/>
<Mention id="M276" type="SpecificInteraction" span="349 31" str="deterioration of renal function " code="314983004: Deteriorating renal function (finding)"/>
<Mention id="M277" type="SpecificInteraction" span="401 19" str=" acute renal failure" code=" 14669001: Acute renal failure syndrome (disorder)"/>
<Mention id="M275" type="Precipitant" span="265 26" str="selective COX-2 inhibitors" code="n0000008288"/>
<Interaction id="I83" type="Pharmacodynamic interaction" trigger="M274" precipitant="M271" effect="M276;M277"/>
<Interaction id="I84" type="Pharmacodynamic interaction" trigger="M274" precipitant="M275" effect="M276;M277"/>
</Sentence>
<Sentence id="128" LabelDrug="Vasotec" section="34073-7">
<SentenceText>Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors): In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including enalapril, may result in deterioration of renal function, including possible acute renal failure.</SentenceText>
<Mention id="M282" type="Trigger" span="339 9" str="result in"/>
<Mention id="M279" type="Precipitant" span="247 6" str="NSAIDs" code="N0000175722"/>
<Mention id="M284" type="SpecificInteraction" span="349 31" str="deterioration of renal function " code="314983004: Deteriorating renal function (finding)"/>
<Mention id="M285" type="SpecificInteraction" span="401 19" str=" acute renal failure" code=" 14669001: Acute renal failure syndrome (disorder)"/>
<Mention id="M283" type="Precipitant" span="265 26" str="selective COX-2 inhibitors" code="n0000008288"/>
<Interaction id="I85" type="Pharmacodynamic interaction" trigger="M282" precipitant="M279" effect="M284;M285"/>
<Interaction id="I86" type="Pharmacodynamic interaction" trigger="M282" precipitant="M283" effect="M284;M285"/>
</Sentence>
<Sentence id="129" LabelDrug="Vasotec" section="34073-7">
<SentenceText>Other Cardiovascular Agents: VASOTEC has been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.</SentenceText>
</Sentence>
<Sentence id="130" LabelDrug="Vasotec" section="34073-7">
<SentenceText>Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.</SentenceText>
<Mention id="M301" type="Trigger" span="167 9" str="increases"/>
<Mention id="M287" type="Precipitant" span="67 9" str="amiloride" code="N0000006772"/>
<Mention id="M303" type="SpecificInteraction" span="167 28" str="increases in serum potassium" code="166689004: Raised serum potassium level (finding)"/>
<Mention id="M290" type="Precipitant" span="79 21" str="potassium supplements" code="N0000175600"/>
<Mention id="M293" type="Precipitant" span="105 37" str="potassium-containing salt substitutes" code="N0000175600"/>
<Mention id="M296" type="Precipitant" span="0 27" str="Potassium-sparing diuretics" code="n0000175418"/>
<Mention id="M299" type="Precipitant" span="35 14" str="spironolactone" code="N0000005900"/>
<Mention id="M302" type="Precipitant" span="51 11" str="triamterene" code="N0000005985"/>
<Interaction id="I87" type="Pharmacodynamic interaction" trigger="M301" precipitant="M287" effect="M303"/>
<Interaction id="I88" type="Pharmacodynamic interaction" trigger="M301" precipitant="M290" effect="M303"/>
<Interaction id="I89" type="Pharmacodynamic interaction" trigger="M301" precipitant="M293" effect="M303"/>
<Interaction id="I90" type="Pharmacodynamic interaction" trigger="M301" precipitant="M296" effect="M303"/>
<Interaction id="I91" type="Pharmacodynamic interaction" trigger="M301" precipitant="M299" effect="M303"/>
<Interaction id="I92" type="Pharmacodynamic interaction" trigger="M301" precipitant="M302" effect="M303"/>
</Sentence>
<Sentence id="130" LabelDrug="Vasotec" section="34073-7">
<SentenceText>Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.</SentenceText>
<Mention id="M319" type="Trigger" span="167 9" str="increases"/>
<Mention id="M305" type="Precipitant" span="67 9" str="amiloride" code="N0000006772"/>
<Mention id="M321" type="SpecificInteraction" span="167 28" str="increases in serum potassium" code="166689004: Raised serum potassium level (finding)"/>
<Mention id="M308" type="Precipitant" span="79 21" str="potassium supplements" code="N0000175600"/>
<Mention id="M311" type="Precipitant" span="105 37" str="potassium-containing salt substitutes" code="N0000175600"/>
<Mention id="M314" type="Precipitant" span="0 27" str="Potassium-sparing diuretics" code="n0000175418"/>
<Mention id="M317" type="Precipitant" span="35 14" str="spironolactone" code="N0000005900"/>
<Mention id="M320" type="Precipitant" span="51 11" str="triamterene" code="N0000005985"/>
<Interaction id="I93" type="Pharmacodynamic interaction" trigger="M319" precipitant="M305" effect="M321"/>
<Interaction id="I94" type="Pharmacodynamic interaction" trigger="M319" precipitant="M308" effect="M321"/>
<Interaction id="I95" type="Pharmacodynamic interaction" trigger="M319" precipitant="M311" effect="M321"/>
<Interaction id="I96" type="Pharmacodynamic interaction" trigger="M319" precipitant="M314" effect="M321"/>
<Interaction id="I97" type="Pharmacodynamic interaction" trigger="M319" precipitant="M317" effect="M321"/>
<Interaction id="I98" type="Pharmacodynamic interaction" trigger="M319" precipitant="M320" effect="M321"/>
</Sentence>
<Sentence id="130" LabelDrug="Vasotec" section="34073-7">
<SentenceText>Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.</SentenceText>
<Mention id="M337" type="Trigger" span="167 9" str="increases"/>
<Mention id="M323" type="Precipitant" span="67 9" str="amiloride" code="N0000006772"/>
<Mention id="M339" type="SpecificInteraction" span="167 28" str="increases in serum potassium" code="166689004: Raised serum potassium level (finding)"/>
<Mention id="M326" type="Precipitant" span="79 21" str="potassium supplements" code="N0000175600"/>
<Mention id="M329" type="Precipitant" span="105 37" str="potassium-containing salt substitutes" code="N0000175600"/>
<Mention id="M332" type="Precipitant" span="0 27" str="Potassium-sparing diuretics" code="n0000175418"/>
<Mention id="M335" type="Precipitant" span="35 14" str="spironolactone" code="N0000005900"/>
<Mention id="M338" type="Precipitant" span="51 11" str="triamterene" code="N0000005985"/>
<Interaction id="I99" type="Pharmacodynamic interaction" trigger="M337" precipitant="M323" effect="M339"/>
<Interaction id="I100" type="Pharmacodynamic interaction" trigger="M337" precipitant="M326" effect="M339"/>
<Interaction id="I101" type="Pharmacodynamic interaction" trigger="M337" precipitant="M329" effect="M339"/>
<Interaction id="I102" type="Pharmacodynamic interaction" trigger="M337" precipitant="M332" effect="M339"/>
<Interaction id="I103" type="Pharmacodynamic interaction" trigger="M337" precipitant="M335" effect="M339"/>
<Interaction id="I104" type="Pharmacodynamic interaction" trigger="M337" precipitant="M338" effect="M339"/>
</Sentence>
<Sentence id="130" LabelDrug="Vasotec" section="34073-7">
<SentenceText>Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.</SentenceText>
<Mention id="M355" type="Trigger" span="167 9" str="increases"/>
<Mention id="M341" type="Precipitant" span="67 9" str="amiloride" code="N0000006772"/>
<Mention id="M357" type="SpecificInteraction" span="167 28" str="increases in serum potassium" code="166689004: Raised serum potassium level (finding)"/>
<Mention id="M344" type="Precipitant" span="79 21" str="potassium supplements" code="N0000175600"/>
<Mention id="M347" type="Precipitant" span="105 37" str="potassium-containing salt substitutes" code="N0000175600"/>
<Mention id="M350" type="Precipitant" span="0 27" str="Potassium-sparing diuretics" code="n0000175418"/>
<Mention id="M353" type="Precipitant" span="35 14" str="spironolactone" code="N0000005900"/>
<Mention id="M356" type="Precipitant" span="51 11" str="triamterene" code="N0000005985"/>
<Interaction id="I105" type="Pharmacodynamic interaction" trigger="M355" precipitant="M341" effect="M357"/>
<Interaction id="I106" type="Pharmacodynamic interaction" trigger="M355" precipitant="M344" effect="M357"/>
<Interaction id="I107" type="Pharmacodynamic interaction" trigger="M355" precipitant="M347" effect="M357"/>
<Interaction id="I108" type="Pharmacodynamic interaction" trigger="M355" precipitant="M350" effect="M357"/>
<Interaction id="I109" type="Pharmacodynamic interaction" trigger="M355" precipitant="M353" effect="M357"/>
<Interaction id="I110" type="Pharmacodynamic interaction" trigger="M355" precipitant="M356" effect="M357"/>
</Sentence>
<Sentence id="130" LabelDrug="Vasotec" section="34073-7">
<SentenceText>Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.</SentenceText>
<Mention id="M373" type="Trigger" span="167 9" str="increases"/>
<Mention id="M359" type="Precipitant" span="67 9" str="amiloride" code="N0000006772"/>
<Mention id="M375" type="SpecificInteraction" span="167 28" str="increases in serum potassium" code="166689004: Raised serum potassium level (finding)"/>
<Mention id="M362" type="Precipitant" span="79 21" str="potassium supplements" code="N0000175600"/>
<Mention id="M365" type="Precipitant" span="105 37" str="potassium-containing salt substitutes" code="N0000175600"/>
<Mention id="M368" type="Precipitant" span="0 27" str="Potassium-sparing diuretics" code="n0000175418"/>
<Mention id="M371" type="Precipitant" span="35 14" str="spironolactone" code="N0000005900"/>
<Mention id="M374" type="Precipitant" span="51 11" str="triamterene" code="N0000005985"/>
<Interaction id="I111" type="Pharmacodynamic interaction" trigger="M373" precipitant="M359" effect="M375"/>
<Interaction id="I112" type="Pharmacodynamic interaction" trigger="M373" precipitant="M362" effect="M375"/>
<Interaction id="I113" type="Pharmacodynamic interaction" trigger="M373" precipitant="M365" effect="M375"/>
<Interaction id="I114" type="Pharmacodynamic interaction" trigger="M373" precipitant="M368" effect="M375"/>
<Interaction id="I115" type="Pharmacodynamic interaction" trigger="M373" precipitant="M371" effect="M375"/>
<Interaction id="I116" type="Pharmacodynamic interaction" trigger="M373" precipitant="M374" effect="M375"/>
</Sentence>
<Sentence id="130" LabelDrug="Vasotec" section="34073-7">
<SentenceText>Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.</SentenceText>
<Mention id="M391" type="Trigger" span="167 9" str="increases"/>
<Mention id="M377" type="Precipitant" span="67 9" str="amiloride" code="N0000006772"/>
<Mention id="M393" type="SpecificInteraction" span="167 28" str="increases in serum potassium" code="166689004: Raised serum potassium level (finding)"/>
<Mention id="M380" type="Precipitant" span="79 21" str="potassium supplements" code="N0000175600"/>
<Mention id="M383" type="Precipitant" span="105 37" str="potassium-containing salt substitutes" code="N0000175600"/>
<Mention id="M386" type="Precipitant" span="0 27" str="Potassium-sparing diuretics" code="n0000175418"/>
<Mention id="M389" type="Precipitant" span="35 14" str="spironolactone" code="N0000005900"/>
<Mention id="M392" type="Precipitant" span="51 11" str="triamterene" code="N0000005985"/>
<Interaction id="I117" type="Pharmacodynamic interaction" trigger="M391" precipitant="M377" effect="M393"/>
<Interaction id="I118" type="Pharmacodynamic interaction" trigger="M391" precipitant="M380" effect="M393"/>
<Interaction id="I119" type="Pharmacodynamic interaction" trigger="M391" precipitant="M383" effect="M393"/>
<Interaction id="I120" type="Pharmacodynamic interaction" trigger="M391" precipitant="M386" effect="M393"/>
<Interaction id="I121" type="Pharmacodynamic interaction" trigger="M391" precipitant="M389" effect="M393"/>
<Interaction id="I122" type="Pharmacodynamic interaction" trigger="M391" precipitant="M392" effect="M393"/>
</Sentence>
<Sentence id="131" LabelDrug="Vasotec" section="34073-7">
<SentenceText>Therefore, if concomitant use of these agents is indicated because of demonstrated hypokalemia, they should be used with caution and with frequent monitoring of serum potassium.</SentenceText>
</Sentence>
<Sentence id="132" LabelDrug="Vasotec" section="42232-9">
<SentenceText>A few cases of lithium toxicity have been reported in patients receiving concomitant VASOTEC and lithium and were reversible upon discontinuation of both drugs .</SentenceText>
<Mention id="M394" type="Trigger" span="23 8" str="toxicity"/>
<Mention id="M395" type="Precipitant" span="15 7" str="lithium" code="N0000147892"/>
<Interaction id="I123" type="Pharmacokinetic interaction" trigger="M394" precipitant="M395" effect="C54357"/>
</Sentence>
<Sentence id="133" LabelDrug="Vasotec" section="42232-9">
<SentenceText>Angioedema , including laryngeal edema , may occur at any time during treatment with angiotensin converting enzyme inhibitors , including enalapril .</SentenceText>
</Sentence>
<Sentence id="134" LabelDrug="Vasotec" section="42232-9">
<SentenceText>Antihypertensive effects of VASOTEC have been established in hypertensive pediatric patients age 1 month to 16 years .</SentenceText>
</Sentence>
<Sentence id="135" LabelDrug="Vasotec" section="42232-9">
<SentenceText>As with all vasodilators , enalapril should be given with caution to patients with obstruction in the outflow tract of the left ventricle .</SentenceText>
</Sentence>
<Sentence id="136" LabelDrug="Vasotec" section="42232-9">
<SentenceText>Avoid use of aliskiren with VASOTEC in patients with renal impairment ( GFR 60 mL/min ) .</SentenceText>
<Mention id="M396" type="Trigger" span="0 5" str="Avoid"/>
<Mention id="M397" type="Precipitant" span="13 9" str="aliskiren" code="N0000176084"/>
<Interaction id="I124" type="Unspecified interaction" trigger="M396" precipitant="M397"/>
</Sentence>
<Sentence id="137" LabelDrug="Vasotec" section="42232-9">
<SentenceText>Closely monitor blood pressure , renal function , and electrolytes in patients on VASOTEC and other agents that affect the RAS .</SentenceText>
</Sentence>
<Sentence id="138" LabelDrug="Vasotec" section="42232-9">
<SentenceText>Do not coadminister aliskiren with VASOTEC in patients with diabetes .</SentenceText>
<Mention id="M398" type="Trigger" span="0 19" str="Do not coadminister"/>
<Mention id="M399" type="Precipitant" span="20 9" str="aliskiren" code="N0000176084"/>
<Interaction id="I125" type="Unspecified interaction" trigger="M398" precipitant="M399"/>
</Sentence>
<Sentence id="139" LabelDrug="Vasotec" section="42232-9">
<SentenceText>Dosage reduction and/or discontinuation of the diuretic and/or VASOTEC may be required .</SentenceText>
<Mention id="M400" type="Trigger" span="0 16" str="Dosage reduction "/>
<Mention id="M401" type="Trigger" span="24 15" str=" discontinuation"/>
<Mention id="M402" type="Precipitant" span="47 8" str="diuretic" code="N0000029125"/>
<Interaction id="I126" type="Unspecified interaction" trigger="M400;M401" precipitant="M402"/>
</Sentence>
<Sentence id="140" LabelDrug="Vasotec" section="42232-9">
<SentenceText>Enalapril and enalaprilat have been detected in human breast milk .</SentenceText>
</Sentence>
<Sentence id="141" LabelDrug="Vasotec" section="42232-9">
<SentenceText>In a clinical pharmacology study , indomethacin or sulindac was administered to hypertensive patients receiving VASOTEC .</SentenceText>
</Sentence>
<Sentence id="142" LabelDrug="Vasotec" section="42232-9">
<SentenceText>In patients undergoing major surgery or during anesthesia with agents that produce hypotension , enalapril may block angiotensin II formation secondary to compensatory renin release .</SentenceText>
</Sentence>
<Sentence id="143" LabelDrug="Vasotec" section="42232-9">
<SentenceText>In patients who are elderly , volume-depleted ( including those on diuretic therapy ) , or with compromised renal function , coadministration of NSAIDs , including selective COX-2 inhibitors , with ACE inhibitors , including enalapril , may result in deterioration of renal function , including possible acute renal failure .</SentenceText>
<Mention id="M407" type="Trigger" span="241 9" str="result in"/>
<Mention id="M404" type="Precipitant" span="145 6" str="NSAIDs" code="N0000175722"/>
<Mention id="M409" type="SpecificInteraction" span="251 31" str="deterioration of renal function " code="314983004: Deteriorating renal function (finding)"/>
<Mention id="M410" type="SpecificInteraction" span="304 19" str=" acute renal failure" code=" 14669001: Acute renal failure syndrome (disorder)"/>
<Mention id="M408" type="Precipitant" span="164 26" str="selective COX-2 inhibitors" code="n0000008288"/>
<Interaction id="I127" type="Pharmacodynamic interaction" trigger="M407" precipitant="M404" effect="M409;M410"/>
<Interaction id="I128" type="Pharmacodynamic interaction" trigger="M407" precipitant="M408" effect="M409;M410"/>
</Sentence>
<Sentence id="143" LabelDrug="Vasotec" section="42232-9">
<SentenceText>In patients who are elderly , volume-depleted ( including those on diuretic therapy ) , or with compromised renal function , coadministration of NSAIDs , including selective COX-2 inhibitors , with ACE inhibitors , including enalapril , may result in deterioration of renal function , including possible acute renal failure .</SentenceText>
<Mention id="M415" type="Trigger" span="241 9" str="result in"/>
<Mention id="M412" type="Precipitant" span="145 6" str="NSAIDs" code="N0000175722"/>
<Mention id="M417" type="SpecificInteraction" span="251 31" str="deterioration of renal function " code="314983004: Deteriorating renal function (finding)"/>
<Mention id="M418" type="SpecificInteraction" span="304 19" str=" acute renal failure" code=" 14669001: Acute renal failure syndrome (disorder)"/>
<Mention id="M416" type="Precipitant" span="164 26" str="selective COX-2 inhibitors" code="n0000008288"/>
<Interaction id="I129" type="Pharmacodynamic interaction" trigger="M415" precipitant="M412" effect="M417;M418"/>
<Interaction id="I130" type="Pharmacodynamic interaction" trigger="M415" precipitant="M416" effect="M417;M418"/>
</Sentence>
<Sentence id="144" LabelDrug="Vasotec" section="42232-9">
<SentenceText>In patients with severe heart failure whose renal function may depend on the activity of the renin-angiotensin-aldosterone system , treatment with angiotensin converting enzyme inhibitors , including VASOTEC , may be associated with oliguria and/or progressive azotemia and rarely with acute renal failure and/or death ( see PRECAUTIONS , Drug Interactions ) .</SentenceText>
</Sentence>
<Sentence id="145" LabelDrug="Vasotec" section="42232-9">
<SentenceText>In this study there was no evidence of a blunting of the antihypertensive action of VASOTEC .</SentenceText>
</Sentence>
<Sentence id="146" LabelDrug="Vasotec" section="42232-9">
<SentenceText>It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium .</SentenceText>
<Mention id="M419" type="Trigger" span="47 9" str="monitored"/>
<Mention id="M420" type="Precipitant" span="29 7" str="lithium" code="N0000147892"/>
<Interaction id="I131" type="Unspecified interaction" trigger="M419" precipitant="M420"/>
</Sentence>
<Sentence id="147" LabelDrug="Vasotec" section="42232-9">
<SentenceText>Monitor renal function periodically in patients receiving enalapril and NSAID therapy .</SentenceText>
<Mention id="M421" type="Trigger" span="0 22" str="Monitor renal function"/>
<Mention id="M422" type="Precipitant" span="72 5" str="NSAID" code="N0000175722"/>
<Interaction id="I132" type="Unspecified interaction" trigger="M421" precipitant="M422"/>
</Sentence>
<Sentence id="148" LabelDrug="Vasotec" section="42232-9">
<SentenceText>Nitritoid reactions ( symptoms include facial flushing , nausea , vomiting and hypotension ) have been reported rarely in patients on therapy with injectable gold ( sodium aurothiomalate ) and concomitant ACE inhibitor therapy including VASOTEC .</SentenceText>
<Mention id="M430" type="Trigger" span="10 9;22 8" str="reactions | symptoms"/>
<Mention id="M424" type="Precipitant" span="147 15" str="injectable gold" code="N0000005996"/>
<Mention id="M432" type="SpecificInteraction" span="0 19" str="Nitritoid reactions " code="426711003: Nitritoid reaction (disorder)"/>
<Mention id="M433" type="SpecificInteraction" span="39 15" str=" facial flushing " code=" 238810007: Flushing (disorder)"/>
<Mention id="M434" type="SpecificInteraction" span="57 6" str=" nausea " code="  422587007: Nausea (finding)"/>
<Mention id="M435" type="SpecificInteraction" span="66 8" str=" vomiting " code=" 422400008: Vomiting (disorder)"/>
<Mention id="M436" type="SpecificInteraction" span="79 11" str=" hypotension" code=" 45007003: Low blood pressure (disorder)"/>
<Mention id="M431" type="Precipitant" span="165 21" str="sodium aurothiomalate" code="N0000006015"/>
<Interaction id="I133" type="Pharmacodynamic interaction" trigger="M430" precipitant="M424" effect="M432;M433;M434;M435;M436"/>
<Interaction id="I134" type="Pharmacodynamic interaction" trigger="M430" precipitant="M431" effect="M432;M433;M434;M435;M436"/>
</Sentence>
<Sentence id="148" LabelDrug="Vasotec" section="42232-9">
<SentenceText>Nitritoid reactions ( symptoms include facial flushing , nausea , vomiting and hypotension ) have been reported rarely in patients on therapy with injectable gold ( sodium aurothiomalate ) and concomitant ACE inhibitor therapy including VASOTEC .</SentenceText>
<Mention id="M444" type="Trigger" span="10 9;22 8" str="reactions | symptoms"/>
<Mention id="M438" type="Precipitant" span="147 15" str="injectable gold" code="N0000005996"/>
<Mention id="M446" type="SpecificInteraction" span="0 19" str="Nitritoid reactions " code="426711003: Nitritoid reaction (disorder)"/>
<Mention id="M447" type="SpecificInteraction" span="39 15" str=" facial flushing " code=" 238810007: Flushing (disorder)"/>
<Mention id="M448" type="SpecificInteraction" span="57 6" str=" nausea " code="  422587007: Nausea (finding)"/>
<Mention id="M449" type="SpecificInteraction" span="66 8" str=" vomiting " code=" 422400008: Vomiting (disorder)"/>
<Mention id="M450" type="SpecificInteraction" span="79 11" str=" hypotension" code=" 45007003: Low blood pressure (disorder)"/>
<Mention id="M445" type="Precipitant" span="165 21" str="sodium aurothiomalate" code="N0000006015"/>
<Interaction id="I135" type="Pharmacodynamic interaction" trigger="M444" precipitant="M438" effect="M446;M447;M448;M449;M450"/>
<Interaction id="I136" type="Pharmacodynamic interaction" trigger="M444" precipitant="M445" effect="M446;M447;M448;M449;M450"/>
</Sentence>
<Sentence id="149" LabelDrug="Vasotec" section="42232-9">
<SentenceText>Patients on diuretics and especially those in whom diuretic therapy was recently instituted , may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril .</SentenceText>
<Mention id="M451" type="Trigger" span="111 10;135 9" str="experience | reduction"/>
<Mention id="M452" type="Precipitant" span="12 9" str="diuretics" code="N0000029125"/>
<Mention id="M453" type="SpecificInteraction" span="135 27" str="reduction of blood pressure" code="12763006: Finding of decreased blood pressure (finding)"/>
<Interaction id="I137" type="Pharmacodynamic interaction" trigger="M451" precipitant="M452" effect="M453"/>
</Sentence>
<Sentence id="150" LabelDrug="Vasotec" section="42232-9">
<SentenceText>Potassium-sparing agents should generally not be used in patients with heart failure receiving VASOTEC .</SentenceText>
<Mention id="M454" type="Trigger" span="25 6;42 11" str="should | not be used"/>
<Mention id="M455" type="Precipitant" span="0 24" str="Potassium-sparing agents" code="n0000175418"/>
<Interaction id="I138" type="Unspecified interaction" trigger="M454" precipitant="M455"/>
</Sentence>
<Sentence id="151" LabelDrug="Vasotec" section="42232-9">
<SentenceText>Risk factors for the development of hyperkalemia include renal insufficiency , diabetes mellitus , and the concomitant use of potassium-sparing diuretics , potassium supplements and/or potassium-containing salt substitutes , which should be used cautiously , if at all , with VASOTEC ( see Drug Interactions ) .</SentenceText>
<Mention id="M462" type="Trigger" span="246 10" str="cautiously"/>
<Mention id="M457" type="Precipitant" span="156 21" str="potassium supplements" code="N0000175600"/>
<Mention id="M464" type="SpecificInteraction" span="36 12" str="hyperkalemia" code="14140009: Hyperkalemia (disorder)"/>
<Mention id="M460" type="Precipitant" span="185 37" str="potassium-containing salt substitutes" code="N0000175600"/>
<Mention id="M463" type="Precipitant" span="126 27" str="potassium-sparing diuretics" code="N0000175418"/>
<Interaction id="I139" type="Pharmacodynamic interaction" trigger="M462" precipitant="M457" effect="M464"/>
<Interaction id="I140" type="Pharmacodynamic interaction" trigger="M462" precipitant="M460" effect="M464"/>
<Interaction id="I141" type="Pharmacodynamic interaction" trigger="M462" precipitant="M463" effect="M464"/>
</Sentence>
<Sentence id="151" LabelDrug="Vasotec" section="42232-9">
<SentenceText>Risk factors for the development of hyperkalemia include renal insufficiency , diabetes mellitus , and the concomitant use of potassium-sparing diuretics , potassium supplements and/or potassium-containing salt substitutes , which should be used cautiously , if at all , with VASOTEC ( see Drug Interactions ) .</SentenceText>
<Mention id="M471" type="Trigger" span="246 10" str="cautiously"/>
<Mention id="M466" type="Precipitant" span="156 21" str="potassium supplements" code="N0000175600"/>
<Mention id="M473" type="SpecificInteraction" span="36 12" str="hyperkalemia" code="14140009: Hyperkalemia (disorder)"/>
<Mention id="M469" type="Precipitant" span="185 37" str="potassium-containing salt substitutes" code="N0000175600"/>
<Mention id="M472" type="Precipitant" span="126 27" str="potassium-sparing diuretics" code="N0000175418"/>
<Interaction id="I142" type="Pharmacodynamic interaction" trigger="M471" precipitant="M466" effect="M473"/>
<Interaction id="I143" type="Pharmacodynamic interaction" trigger="M471" precipitant="M469" effect="M473"/>
<Interaction id="I144" type="Pharmacodynamic interaction" trigger="M471" precipitant="M472" effect="M473"/>
</Sentence>
<Sentence id="151" LabelDrug="Vasotec" section="42232-9">
<SentenceText>Risk factors for the development of hyperkalemia include renal insufficiency , diabetes mellitus , and the concomitant use of potassium-sparing diuretics , potassium supplements and/or potassium-containing salt substitutes , which should be used cautiously , if at all , with VASOTEC ( see Drug Interactions ) .</SentenceText>
<Mention id="M480" type="Trigger" span="246 10" str="cautiously"/>
<Mention id="M475" type="Precipitant" span="156 21" str="potassium supplements" code="N0000175600"/>
<Mention id="M482" type="SpecificInteraction" span="36 12" str="hyperkalemia" code="14140009: Hyperkalemia (disorder)"/>
<Mention id="M478" type="Precipitant" span="185 37" str="potassium-containing salt substitutes" code="N0000175600"/>
<Mention id="M481" type="Precipitant" span="126 27" str="potassium-sparing diuretics" code="N0000175418"/>
<Interaction id="I145" type="Pharmacodynamic interaction" trigger="M480" precipitant="M475" effect="M482"/>
<Interaction id="I146" type="Pharmacodynamic interaction" trigger="M480" precipitant="M478" effect="M482"/>
<Interaction id="I147" type="Pharmacodynamic interaction" trigger="M480" precipitant="M481" effect="M482"/>
</Sentence>
<Sentence id="152" LabelDrug="Vasotec" section="42232-9">
<SentenceText>Some patients with hypertension or heart failure with no apparent pre-existing renal vascular disease have developed increases in blood urea and serum creatinine , usually minor and transient , especially when VASOTEC has been given concomitantly with a diuretic .</SentenceText>
<Mention id="M483" type="Trigger" span="107 19" str="developed increases"/>
<Mention id="M484" type="Precipitant" span="254 8" str="diuretic" code="N0000029125"/>
<Mention id="M485" type="SpecificInteraction" span="117 9;130 10" str="increases | blood urea " code="166712009: Blood urea abnormal (finding)"/>
<Mention id="M486" type="SpecificInteraction" span="117 9;145 16" str=" increases | serum creatinine" code=" 166717003: Serum creatinine raised (finding)"/>
<Interaction id="I148" type="Pharmacodynamic interaction" trigger="M483" precipitant="M484" effect="M485;M486"/>
</Sentence>
<Sentence id="153" LabelDrug="Vasotec" section="42232-9">
<SentenceText>The antihypertensive effect of VASOTEC is augmented by antihypertensive agents that cause renin release ( e.g. , diuretics ) .</SentenceText>
<Mention id="M490" type="Trigger" span="21 6;42 9" str="effect | augmented"/>
<Mention id="M488" type="Precipitant" span="55 48" str="antihypertensive agents that cause renin release" code="NO MAP"/>
<Mention id="M492" type="SpecificInteraction" span="4 23;42 9" str="antihypertensive effect | augmented" code="NO MAP"/>
<Mention id="M491" type="Precipitant" span="113 9" str="diuretics" code="N0000029125"/>
<Interaction id="I149" type="Pharmacodynamic interaction" trigger="M490" precipitant="M488" effect="M492"/>
<Interaction id="I150" type="Pharmacodynamic interaction" trigger="M490" precipitant="M491" effect="M492"/>
</Sentence>
<Sentence id="153" LabelDrug="Vasotec" section="42232-9">
<SentenceText>The antihypertensive effect of VASOTEC is augmented by antihypertensive agents that cause renin release ( e.g. , diuretics ) .</SentenceText>
<Mention id="M496" type="Trigger" span="21 6;42 9" str="effect | augmented"/>
<Mention id="M494" type="Precipitant" span="55 48" str="antihypertensive agents that cause renin release" code="NO MAP"/>
<Mention id="M498" type="SpecificInteraction" span="4 23;42 9" str="antihypertensive effect | augmented" code="NO MAP"/>
<Mention id="M497" type="Precipitant" span="113 9" str="diuretics" code="N0000029125"/>
<Interaction id="I151" type="Pharmacodynamic interaction" trigger="M496" precipitant="M494" effect="M498"/>
<Interaction id="I152" type="Pharmacodynamic interaction" trigger="M496" precipitant="M497" effect="M498"/>
</Sentence>
<Sentence id="154" LabelDrug="Vasotec" section="42232-9">
<SentenceText>The possibility of hypotensive effects with enalapril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril .</SentenceText>
<Mention id="M499" type="Trigger" span="31 7;61 12;81 13" str="effects | minimized by | discontinuing"/>
<Mention id="M500" type="Precipitant" span="99 8" str="diuretic" code="N0000029125"/>
<Mention id="M501" type="SpecificInteraction" span="19 19" str="hypotensive effects" code="45007003: Low blood pressure (disorder)"/>
<Interaction id="I153" type="Pharmacodynamic interaction" trigger="M499" precipitant="M500" effect="M501"/>
</Sentence>
<Sentence id="155" LabelDrug="Vasotec" section="42232-9">
<SentenceText>VASOTEC attenuates potassium loss caused by thiazide-type diuretics .</SentenceText>
<Mention id="M504" type="SpecificInteraction" span="8 25" str="attenuates potassium loss" code="NO MAP"/>
<Mention id="M503" type="Precipitant" span="44 23" str="thiazide-type diuretics" code="N0000029126"/>
<Interaction id="I154" type="Pharmacodynamic interaction" trigger="M504" precipitant="M503" effect="M504"/>
</Sentence>
<Sentence id="156" LabelDrug="Vasotec" section="42232-9">
<SentenceText>VASOTEC has been used concomitantly with beta adrenergic-blocking agents , methyldopa , nitrates , calcium-blocking agents , hydralazine , prazosin and digoxin without evidence of clinically significant adverse interactions .</SentenceText>
</Sentence>
</Sentences>
<LabelInteractions><LabelInteraction type="Pharmacodynamic interaction" precipitant="potassium salt substitutes" precipitantCode="N0000175600" effect="166689004: Raised serum potassium level (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="potassium supplements" precipitantCode="N0000175600" effect="14140009: Hyperkalemia (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="potassium supplements" precipitantCode="N0000175600" effect="166689004: Raised serum potassium level (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="potassium-sparing diuretics" precipitantCode="N0000175418" effect="14140009: Hyperkalemia (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="potassium-sparing diuretics" precipitantCode="N0000175418" effect="166689004: Raised serum potassium level (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="diuretic" precipitantCode="N0000029125" effect=" 166717003: Serum creatinine raised (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="diuretic" precipitantCode="N0000029125" effect="166712009: Blood urea abnormal (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="diuretic" precipitantCode="N0000029125" effect="45007003: Low blood pressure (disorder)"/>
<LabelInteraction type="Unspecified interaction" precipitant="diuretic" precipitantCode="N0000029125"/>
<LabelInteraction type="Unspecified interaction" precipitant="neprilysin inhibitor" precipitantCode="N0000191728"/>
<LabelInteraction type="Unspecified interaction" precipitant="sacubitril/valsartan" precipitantCode="N0000191740"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="aliskiren" precipitantCode="N0000176084" effect=" 14140009: Hyperkalemia (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="aliskiren" precipitantCode="N0000176084" effect=" 14669001: Acute renal failure syndrome (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="aliskiren" precipitantCode="N0000176084" effect=" 39539005: Abnormal renal function (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="aliskiren" precipitantCode="N0000176084" effect="45007003: Low blood pressure (disorder)"/>
<LabelInteraction type="Unspecified interaction" precipitant="aliskiren" precipitantCode="N0000176084"/>
<LabelInteraction type="Unspecified interaction" precipitant="sacubitril" precipitantCode="N0000191735"/>
<LabelInteraction type="Unspecified interaction" precipitant="eicosanoids" precipitantCode="n0000008271"/>
<LabelInteraction type="Unspecified interaction" precipitant="endogenous bradykinin" precipitantCode="NO MAP"/>
<LabelInteraction type="Unspecified interaction" precipitant="polypeptides" precipitantCode="NO MAP"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="ace inhibitors" precipitantCode="N0000029130" effect=" 14140009: Hyperkalemia (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="ace inhibitors" precipitantCode="N0000029130" effect=" 14669001: Acute renal failure syndrome (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="ace inhibitors" precipitantCode="N0000029130" effect=" 39539005: Abnormal renal function (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="ace inhibitors" precipitantCode="N0000029130" effect="45007003: Low blood pressure (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="angiotensin receptor blockers" precipitantCode="N0000000070" effect=" 14140009: Hyperkalemia (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="angiotensin receptor blockers" precipitantCode="N0000000070" effect=" 14669001: Acute renal failure syndrome (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="angiotensin receptor blockers" precipitantCode="N0000000070" effect=" 39539005: Abnormal renal function (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="angiotensin receptor blockers" precipitantCode="N0000000070" effect="45007003: Low blood pressure (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="agents causing renin release" precipitantCode="NO MAP" effect="163036009: On examination - blood pressure decreased (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="antihypertensive agents that cause renin release" precipitantCode="NO MAP" effect="163036009: On examination - blood pressure decreased (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="antihypertensive agents that cause renin release" precipitantCode="NO MAP" effect="NO MAP"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="diuretics" precipitantCode="N0000029125" effect="12763006: Finding of decreased blood pressure (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="diuretics" precipitantCode="N0000029125" effect="163036009: On examination - blood pressure decreased (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="diuretics" precipitantCode="N0000029125" effect="NO MAP"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="thiazide-type diuretics" precipitantCode="N0000029126" effect="NO MAP"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="neprilysin inhibitors" precipitantCode="NO MAP" effect="41291007: Angioedema (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="everolimus" precipitantCode="N0000178379" effect="41291007: Angioedema (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="mtor | inhibitors" precipitantCode="n0000175624" effect="41291007: Angioedema (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="sirolimus" precipitantCode="N0000006605" effect="41291007: Angioedema (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="sodium aurothiomalate" precipitantCode="N0000006015" effect="  422587007: Nausea (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="sodium aurothiomalate" precipitantCode="N0000006015" effect=" 238810007: Flushing (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="sodium aurothiomalate" precipitantCode="N0000006015" effect=" 422400008: Vomiting (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="sodium aurothiomalate" precipitantCode="N0000006015" effect=" 45007003: Low blood pressure (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="sodium aurothiomalate" precipitantCode="N0000006015" effect="426711003: Nitritoid reaction (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="temsirolimus" precipitantCode="N0000176108" effect="41291007: Angioedema (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="nsaids" precipitantCode="N0000175722" effect=" 14669001: Acute renal failure syndrome (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="nsaids" precipitantCode="N0000175722" effect="314983004: Deteriorating renal function (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="nsaids" precipitantCode="N0000175722" effect="NO MAP"/>
<LabelInteraction type="Unspecified interaction" precipitant="ras inhibitors" precipitantCode="NO MAP"/>
<LabelInteraction type="Pharmacokinetic interaction" precipitant="lithium" precipitantCode="N0000147892" effect="C54357"/>
<LabelInteraction type="Unspecified interaction" precipitant="lithium" precipitantCode="N0000147892"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="selective cox-2 inhibitors" precipitantCode="n0000008288" effect=" 14669001: Acute renal failure syndrome (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="selective cox-2 inhibitors" precipitantCode="n0000008288" effect="314983004: Deteriorating renal function (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="amiloride" precipitantCode="N0000006772" effect="166689004: Raised serum potassium level (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="potassium-containing salt substitutes" precipitantCode="N0000175600" effect="14140009: Hyperkalemia (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="potassium-containing salt substitutes" precipitantCode="N0000175600" effect="166689004: Raised serum potassium level (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="potassium-sparing diuretics" precipitantCode="n0000175418" effect="166689004: Raised serum potassium level (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="spironolactone" precipitantCode="N0000005900" effect="166689004: Raised serum potassium level (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="triamterene" precipitantCode="N0000005985" effect="166689004: Raised serum potassium level (finding)"/>
<LabelInteraction type="Unspecified interaction" precipitant="nsaid" precipitantCode="N0000175722"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="injectable gold" precipitantCode="N0000005996" effect="  422587007: Nausea (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="injectable gold" precipitantCode="N0000005996" effect=" 238810007: Flushing (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="injectable gold" precipitantCode="N0000005996" effect=" 422400008: Vomiting (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="injectable gold" precipitantCode="N0000005996" effect=" 45007003: Low blood pressure (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="injectable gold" precipitantCode="N0000005996" effect="426711003: Nitritoid reaction (disorder)"/>
<LabelInteraction type="Unspecified interaction" precipitant="potassium-sparing agents" precipitantCode="n0000175418"/>

</LabelInteractions></Label>